Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Earnings Report Card Additions, Q3/11, Regenerative Medicine Universe

Report Card Additions … so far …

 

An earnings release is a ‘report card’ of sorts for a public stem cell company. The current LPS (loss per share) standings reflect the universes’ investing status. By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity of stem cell research and whether or not it deserves their investment.

 

For Q3/11 ending 9/30/11, earnings continue to be announced:

  • Osiris (NASDAQ:OSIR) net income of $4M or $0.12 per share with $53.3M cash and receivables;
  • StemCells (STEM) net loss of $4.33M or $0.31 per share with $12.53M in cash;
  • Cytori (NASDAQ:CYTX) net loss of $8.335M or $0.15 per share with $40.8M in cash plus $2M in receivables;
  • Geron (NASDAQ:GERN) net loss of $19.5M or $0.16 per share with $180.8M in cash;
  • Aastrom (ASTM) net loss of  $1.9M or $0.05 per share with $11.9M in cash;
  • ThermoGenesis (Q1/12) net loss of $1.2M or $0.07 per share with $12.3M in cash;

 

Additions:

  • BioMimetic (NASDAQ:BMTI) a net loss of $7.1M or $0.25 per share and $66.8M in cash;
  • NeoStem (AMEX: NBS)  a net loss of $7.97M or $0.08 per share with $11.7M in cash, restricted cash of  $1.42M and account receivable of which $8.9M;
  • International Stem Cell (OTC BB: ISCO) net loss of $2.672M or $0.03 per share with $2.58M in cash;
  • Tengion (TNGN) adjusted net loss of  $5.1M or $0.21 per share with $20.3M in cash;
  • Athersys (NASDAQ:ATHX) net loss of $2.34M or $0.10 per share with $16.5M in cash;
  • BioTime (AMEX: BTX) net loss of $3.7M or $0.08 per share with $26.2M in cash;